In-vivo Protection from SARS-CoV-2 infection by ATN-161 in k18-hACE2 transgenic mice
A. Narayanappa, E. B. Engler-Chiurazzi, I. C. Murray-Brown, T. E. Gressett, I. J. Biose, W. H. Chastain, G. Bix
This study evaluates the therapeutic potential of ATN-161 in reducing SARS-CoV-2 infection in mice by inhibiting integrin 5β1, showing reduced viral load and improved lung histology.
bioRxiv · May 8, 2021Immunology